Hepatitis B Virus Reactivation After Treatment for Hepatitis C in Hemodialysis Patients with HBV/HCV Coinfection

Overview

Journal Braz J Infect Dis

Specialty Infectious Diseases

Date 2015 May 23

PMID 25997784

Citations 4

Authors

Raul Carlos Wahle

Renata Mello Perez

Patricia Fucuta Pereira

Elze Maria Gomes Oliveira

Christini Takemi Emori

Silvia Naomi de Oliveira Uehara

Ivonete Sandra de Souza Silva

Antonio Eduardo Benedito Silva

Maria Lucia Gomes Ferraz

Affiliations

Soon will be listed here.

Abstract

In coinfected HBV/HCV patients, HBV replication is usually suppressed by HCV over the time. No study to date has evaluated the HBV viremia in long-term follow-up after HCV treatment in hemodialysis patients with HBV/HCV coinfection. This study aimed to assess the evolution of HBV viremia after HCV treatment in this special population. Ten hemodialysis patients with HBV/HCV coinfection with dominant HCV infection (HBV lower than 2000 IU/mL) and significant fibrosis were treated with interferon-alpha 3 MU 3×/week for 12 months and could be followed for at least 36 months after HCV treatment. Six cases of HBV reactivation (60%) during follow-up were observed and 5/6 had been successfully treated for HCV. Patients with HBV reactivation received anti-HBV therapy. Our preliminary findings indicate that treatment of hepatitis C in HBV/HCV coinfected hemodialysis patients may favor HBV reactivation. Thus, continued monitoring of HBV viremia must be recommended and prompt anti-HBV therapy should be implemented.

Citing Articles

Hepatitis B in Pediatric Population: Observational Retrospective Study in Romania.

Pacurar D, Dinulescu A, Jugulete G, Pasarica A, Dijmarescu I Life (Basel). 2024; 14(3).

PMID: 38541675 PMC: 10970939. DOI: 10.3390/life14030348.

Enhanced host immune responses in presence of HCV facilitate HBV clearance in coinfection.

Liu S, Zhao K, Su X, Gao X, Yao Y, Kong R Virol Sin. 2022; 37(3):408-417.

PMID: 35523417 PMC: 9243674. DOI: 10.1016/j.virs.2022.04.001.

HBV-HCV Coinfection: Viral Interactions, Management, and Viral Reactivation.

Mavilia M, Wu G J Clin Transl Hepatol. 2018; 6(3):296-305.

PMID: 30271742 PMC: 6160312. DOI: 10.14218/JCTH.2018.00016.

Hurdles to the Development of Effective HBV Immunotherapies and HCV Vaccines.

Torres-Cornejo A, Lauer G Pathog Immun. 2017; 2(1):102-125.

PMID: 28664194 PMC: 5486412. DOI: 10.20411/pai.v2i1.201.

References

Potthoff A, Berg T, Wedemeyer H . Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin. Scand J Gastroenterol. 2009; 44(12):1487-90. DOI: 10.3109/00365520903329585. View

Vaziri N, Pahl M, Crum A, Norris K . Effect of uremia on structure and function of immune system. J Ren Nutr. 2011; 22(1):149-56. PMC: 3246616. DOI: 10.1053/j.jrn.2011.10.020. View

Liu J, Sheng Y, Hu H, Zhong Q, Wang J, Tong S . The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis. Virol J. 2012; 9:186. PMC: 3511228. DOI: 10.1186/1743-422X-9-186. View

Fabrizi F, Messa P, Basile C, Martin P . Hepatic disorders in chronic kidney disease. Nat Rev Nephrol. 2010; 6(7):395-403. DOI: 10.1038/nrneph.2010.37. View

Fabrizi F, MARTIN P, Dixit V, Kanwal F, Dulai G . HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant. 2005; 5(12):2913-21. DOI: 10.1111/j.1600-6143.2005.01113.x. View

Rapti I, Hadziyannis S . Treatment of special populations with chronic hepatitis B infection. Expert Rev Gastroenterol Hepatol. 2011; 5(3):323-39. DOI: 10.1586/egh.11.7. View

Gordon S, Sherman K . Treatment of HBV/HCV coinfection: releasing the enemy within. Gastroenterology. 2008; 136(2):393-6. DOI: 10.1053/j.gastro.2008.12.017. View

Hung C, Lee C, Lu S, Wang J, Tung H, Chen C . Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. J Gastroenterol Hepatol. 2005; 20(5):727-32. DOI: 10.1111/j.1440-1746.2005.03791.x. View

Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y . Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008; 3(5):1526-33. PMC: 4571158. DOI: 10.2215/CJN.00950208. View

10.

Yu M, Lee C, Chen C, Chuang W, Lu S, Liu C . Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. Hepatology. 2013; 57(6):2135-42. DOI: 10.1002/hep.26266. View

11.

Pipili C, Cholongitas E, Papatheodoridis G . Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. Aliment Pharmacol Ther. 2013; 39(1):35-46. DOI: 10.1111/apt.12538. View

12.

Liu C, Chuang W, Lee C, Yu M, Lu S, Wu S . Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology. 2008; 136(2):496-504.e3. DOI: 10.1053/j.gastro.2008.10.049. View

13.

Raimondo G, Brunetto M, Pontisso P, Smedile A, Maina A, Saitta C . Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology. 2005; 43(1):100-7. DOI: 10.1002/hep.20944. View

14.

Kim Y, Lee J, Kim Y, Jeong S, Kim Y, Yim H . Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus. Korean J Hepatol. 2011; 17(3):199-205. PMC: 3304647. DOI: 10.3350/kjhep.2011.17.3.199. View

15.

Liu C, Chen P, Lai M, Kao J, Jeng Y, Chen D . Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology. 2003; 37(3):568-76. DOI: 10.1053/jhep.2003.50096. View

16.

Yu J, Sun L, Zhao Y, Kang P, Gao J, Li S . Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus. Liver Int. 2009; 29(10):1485-93. DOI: 10.1111/j.1478-3231.2009.02080.x. View

17.

Chuang W, Dai C, Chang W, Lee L, Lin Z, Chen S . Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antivir Ther. 2005; 10(1):125-33. View

18.

. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57(1):167-85. DOI: 10.1016/j.jhep.2012.02.010. View